There is no single global peptide authorization. Medicine status is tied to a named product, formulation, use, population, jurisdiction, and date, while investigations, compounding, advertising, import, and professional practice can involve different authorities.
This comparison is a dated map to the detailed global framework, four jurisdiction briefs, and cross-border online-supply guide; it is general regulatory research, not legal advice.
| Question | United States | EU/EEA | United Kingdom | Canada |
|---|---|---|---|---|
| Authorization | FDA reviews named drug products | EU scientific and authorization roles coexist with national authorities | MHRA operates the UK system | Health Canada authorizes named products |
| A clinical-stage candidate with scientific or public relevance. Investigation is not approval, and a studied exposure is not a recommendation. परिभाषा का स्रोत: Scope and selection methodology · शब्दावली pathway | FDA IND framework | EU clinical-trial system with member-state and EU roles | UK clinical-trial authorization | Health Canada clinical-trial authorization |
| Compounding | Federal sections Sections of the US Food, Drug, and Cosmetic Act covering traditional compounding exemptions (503A) and outsourcing-facility compounding (503B). Under 503A, qualification conditions include a patient-specific prescription requirement; under 503B, conditions cover facility registration and bulk-substance eligibility. परिभाषा का स्रोत: United States regulation brief · शब्दावली and 503B plus state practice rules | National pharmacy and medicines rules vary | UK medicines and pharmacy rules apply | Federal policy boundary plus provincial pharmacy practice |
| Online or research wording | Claims and intended use can trigger drug law | Wording does not create one EU-wide authorization shortcut | Claims, presentation, and intended use matter | Research wording does not itself create market authorization |
| Question | US / FDA | EU / EEA | UK / MHRA | CANADA |
|---|---|---|---|---|
| authorization | FDA product review | EU + national roles | MHRA authorization | Health Canada |
| investigation | IND | CTA system | CTA system | CTA system |
| compounding | 503A / 503B | national rules | UK rules | provincial practice |
| online / RUO | claims control status | no universal shortcut | claims and intent matter | RUO not authorization |
United States
Who decides. FDA handles federal drug approval, investigation, manufacturing, import, and important compounding functions; state authorities retain professional-practice roles, while other federal agencies can have separate advertising or border responsibilities.
Distinctive pathway. The United States brief, verified 2026-08-06, distinguishes approved products, the IND pathway, traditional compounding under section Sections of the US Food, Drug, and Cosmetic Act covering traditional compounding exemptions (503A) and outsourcing-facility compounding (503B). Under 503A, qualification conditions include a patient-specific prescription requirement; under 503B, conditions cover facility registration and bulk-substance eligibility. परिभाषा का स्रोत: United States regulation brief · शब्दावली, outsourcing facilities under section 503B, and time-qualified federal proposals.
Do not infer. An ingredient name, a shortage, a bulk-substance nomination, or research wording does not by itself establish that a product is FDA-approved or lawfully supplied for a specific use.
European Union and EEA
Who decides. EMA provides scientific evaluation in centralized procedures, while the European Commission, national competent authorities, ethics systems, and member-state enforcement and pharmacy rules have distinct functions.
Distinctive pathway. The EU/EEA brief, verified 2026-08-06, separates centralized and national architecture rather than treating EMA as an EU version of FDA with identical powers.
Do not infer. One member state’s practice, investigation, or supply position does not automatically establish authorization or lawful supply across the EU/EEA.
United Kingdom
Who decides. The post-Brexit system places UK medicine authorization and clinical-trial functions with MHRA, alongside other UK bodies responsible for professional standards and enforcement.
Distinctive pathway. The United Kingdom brief, verified 2026-08-06, records the current UK framework separately from the EU column.
Do not infer. An EU authorization, market label, or online disclaimer should not be assumed to answer the current UK product question without checking the applicable UK route and date.
Canada
Who decides. Health Canada sets federal medicine and clinical-trial requirements, while provincial and territorial pharmacy regulators govern professional compounding practice within their mandates.
Distinctive pathway. The Canada brief, verified 2026-08-06, keeps the federal policy boundary and provincial practice regulation visible instead of attributing every compounding decision to one institution.
Do not infer. Research-use-only wording is not Health Canada authorization, and a compounding context is not a universal exemption from product, sale, advertising, or professional-practice rules.
Five-question jurisdiction check
Before stating status, ask: What exact product and formulation is involved? What use and population are claimed? Which regulator or professional body has the relevant role? Is the record authorization, investigation, compounding, enforcement, or a proposal? What verification date and current primary source support the conclusion?
The global framework and cross-border guide explain why answers should not be transferred across borders or institutional roles.